Every 10-Q that GLOBAL TECHS LTD (GTLL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GTLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GTLL filings page.
Global Technologies, Ltd. reports a net loss for the three and nine months ended March 31, 2026 while continuing to operate with a stockholders’ deficiency and going concern uncertainty. For the nine-month period, revenue was $642,822, with shared revenue of $317,315, resulting in net revenue of $325,507 compared with $666,115 a year earlier.
The company recorded a net loss of $170,524 for the nine months, versus net income of $24,055 in the prior-year period, driven by operating expenses of $755,260. A $282,000 non-cash gain on derivative liability partially offset these costs. Cash used in operating activities was $259,830, leaving cash of $38,178 as of March 31, 2026.
Total assets were $42,399 against total liabilities of $1,136,202, resulting in stockholders’ deficiency of $1,093,803 and an accumulated deficit of $167,726,161. The capital structure includes variable-price convertible notes with a related derivative liability of $498,000 and new Series P Preferred Stock issuances totaling $230,000 of proceeds. Management discloses substantial doubt about the company’s ability to continue as a going concern and outlines plans to seek additional financing and partnerships while transitioning its business toward technology-enabled healthcare procurement and advisory services.
Global Technologies, Ltd. filed an amended quarterly report for the six months ended December 31, 2025 after review by its independent auditor. The amendment mainly refines disclosures and classifications in Notes K and L and does not change previously reported totals. The company remains very small, with cash of $41,408, total assets of $45,629, current liabilities of $977,469, and a stockholders’ deficit of $931,840. Net revenue was $136,347 for the quarter and $233,275 year-to-date, with a quarterly net loss of $144,760 but modest six‑month net income of $21,439 helped by a $282,000 gain on derivative liability. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing a cumulative deficit of $167,534,198, negative operating cash flow of $226,600, and dependence on new funding, including deeply discounted convertible notes and preferred stock issuances.
Global Technologies, Ltd. reports very limited improvement in its financial position for the six months ended December 31, 2025. Net revenue fell to $233,275 from $612,124 a year earlier, and operating loss was $245,187. A non‑cash gain of $282,000 from revaluing derivative liabilities turned results into a small net income of $21,439.
Liquidity remains strained: cash was only $41,408, total assets were $45,629, and current liabilities were $977,469, leaving stockholders’ deficiency of $931,840. The company discloses substantial doubt about its ability to continue as a going concern and plans to seek additional funding through partnerships, debt and equity issuances.
Operations are shifting from the now‑idle 10 Fold Services unit toward Primecare Supply, a 503B pharmaceutical procurement platform, and the newly formed GTLL Advisory. A prior acquisition of GOe3, LLC was unwound after milestones were not met, allowing management to refocus on healthcare and technology‑enabled services.
Global Technologies, Ltd reported results for the quarter ended September 30, 2025, showing a small profit driven by a non-cash derivative gain but weak underlying revenue. Net revenue was $96,928, down sharply from $477,542 a year earlier, with one customer providing 100% of sales and two pharmaceutical suppliers supporting operations. Operating expenses were $205,142, producing an operating loss of $108,214, which was offset by a $282,000 gain from revaluing derivative liabilities tied to convertible notes, resulting in net income of $166,199.
Cash increased to $152,977 from $68,108, mainly from a $200,000 private placement of new Series P Preferred Stock. Total liabilities were $944,278 and stockholders’ deficit was $787,080, including an accumulated deficit of $167.4 million. The company highlights substantial doubt about its ability to continue as a going concern and plans to seek additional financing. Strategy is now focused on health-tech subsidiaries Primecare Supply and GTLL Advisory, while legacy ventures like GOe3 have been unwound.